肿瘤细胞治疗研究
ALL SOURCES
Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.
嵌合抗原受体自然杀伤（CAR-NK）细胞疗法已成为一种有前景的免疫治疗模式，具有强效的细胞毒性和良好的安全性。
The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations.
肠道和肝脏通过门静脉循环、胆道、淋巴引流和神经免疫通路构成一个解剖和功能单元。
Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage.
这些发现表明，TSIs 可通过增强 NK 细胞监视来抑制 TM4SF5 介导的肝癌发生。
Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
ABL503 是一种 PDL1 和 4-1BB 双靶向双特异性抗体，可引发显著的叠加性肿瘤生长抑制，并增加耗竭 CD8+ T 细胞的浸润和功能，进而增强 anti-PD1 阻断的抗癌效果。
The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
VACINUS pMHC 与 VACINUS TCR 的预测能力在 8 例 HCC 患者的验证队列中得到证实。
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.
然而，目前的治疗方案成功率仍然很低，约为 30%。
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized control
辅助 CIK 细胞治疗在 RWD 研究和 9 年扩展 RCT 随访中均显著改善 RFS，支持其在 HCC 根治性治疗后降低复发方面具有可重复的获益。这些一致的发现为 CIK 治疗作为 HCC 持久辅助免疫治疗策略的临床实用性提供了有力证据。
Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.
对 163 例患者治疗前 H&E 图像中的免疫/非免疫细胞空间分布，采用 AI/深度学习模型进行了回顾性分析。
HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma.
这些发现表明，HO-1197 是一种有前景的多功能治疗候选药物，具有抗肿瘤、抗血管生成、抗转移和免疫调节特性。
Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia.
调节 MCP1 可增强 NK 细胞对缺氧 HCC 细胞的活性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
